Amgen’s anti-CGRP migraine therapy heads for submission

Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) said both doses of erenumab (AMG 334) met the primary endpoint in the Phase III STRIVE trial to prevent episodic migraine. From baseline to week 24, 70 mg and 140 mg doses erenumab significantly reduced monthly migraine days by 3.2 and 3.7, respectively, vs. 1.8 for placebo.

The partners say they anticipate submitting erenumab to regulators next year. In September, the companies said erenumab met the primary endpoint in ARISE, another Phase III trial to prevent episodic migraine (see BioCentury Extra, Sept. 28). ...